Mesoblast Ltd

NASDAQ:MESO

Mesoblast is a biotechnology company that develops cell-based medicines, especially treatments made from donated adult stem cells. Its main work is to research, test, and seek approval for therapies aimed at hard-to-treat inflammatory and immune-related diseases, as well as some serious spine and heart conditions. The company does not sell a broad range of consumer products. It makes money when its drug candidates are licensed, approved, or commercialized through partners, and potentially through product sales and royalty streams tied to those therapies. Its customers are mainly hospitals, doctors, and larger pharmaceutical partners rather than end consumers. What makes Mesoblast different is that it sits in the cell-therapy part of drug development, where the product is living cells rather than a standard pill or injection. That makes the science, manufacturing, and regulatory path more complex than for many drugmakers, but it also gives the company a focused role as a specialist developer of regenerative medicines.